A nanovaccine induces durable and functional MUC4-targeted T cell responses against pancreatic cancer
Source abstract
Abstract
Vaccination against cancer for prophylaxis or treatment is becoming a viable approach owing to new developments in the identification of novel biomarkers and advances in our understanding of cancer immunology. Furthermore, nanotechnology has resulted in multifunctional delivery platforms with versatile chemistries and tunable release properties. However, despite this impressive progress, immunotherapy with the goal of inducing antigen-specific T cell immunity against pancreatic cancer (PC) remains challenging. Herein, we report the characterization of the long-lived humoral and cellular immunity towards a promising PC antigen (MUC4) after immunization with either polyanhydride or poly(lactic-co-glycolic acid) particle-based adjuvanted vaccines. T cell response dynamics from both draining lymph nodes and spleens after three immunizations were monitored for up to 180 days. Through a systematic characterization of antigen-specific immunity at various timepoints and organs, a dynamic picture of T cell immunity emerges that suggests differentiation and migration of T cells, Th1 cell polarization, polyfunctional CD4+ and CD8+ T cell cytokine expression, and cytotoxicity towards PC cells. Overall, the results showed that MUC4-nanovaccines induced durable MUC4-specific T cell responses both locally and systemically, which portends well for sustained anti-tumor immunity. STATEMENT OF SIGNIFICANCE: Immunotherapy with the goal of inducing antigen-specific T cell immunity against pancreatic cancer (PC) remains challenging. We characterized long-lived humoral and cellular immunity towards a promising PC antigen (MUC4) after immunization with either polyanhydride or poly(lactic-co-glycolic acid) particle-based adjuvanted vaccines. A systematic characterization of antigen-specific immunity at various timepoints and organs uncovered a dynamic picture of T cell immunity that demonstrated differentiation and migration of T cells, Th1 cell polarization, polyfunctional CD4+ and CD8+ T cell cytokine expression, and cytotoxicity towards PC cells. The findings indicated that MUC4 nanovaccines induced durable MUC4-specific T cell responses both locally and systemically, which portends well for sustained anti-tumor immunity.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Glycosylation and Glycoproteins Research · Monoclonal and Polyclonal Antibodies Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (86)
Show source-provided references
1. Cancer statistics, 2025
2. Chemotherapy in pancreatic cancer: a systematic review
3. Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies10.7150/thno.64805 ↗
4. Lymphatic system of the pancreas10.1002/(SICI)1097-0029(19970601)37:5/6<456::AID-JEMT9>3.0.CO;2-B ↗
5. Pancreatic cancer stroma: an update on therapeutic targeting strategies10.1038/s41575-020-0300-1 ↗
6. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I10.1038/s41586-020-2229-5 ↗
7. First FDA approval agnostic of cancer site-when a biomarker defines the indication10.1056/NEJMp1709968 ↗
8. Results from a phase IIb, randomized, multicenter study of GVAX pancreas and CRS-207 compared with chemotherapy in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE study)10.1158/1078-0432.CCR-18-2992 ↗
9. Vaccines against intracellular infections requiring cellular immunity10.1038/35021239 ↗
10. Defining memory CD8 T cell10.3389/fimmu.2018.02692 ↗
11. Functional differences between memory and naive CD8 T cells10.1073/pnas.96.6.2976 ↗
12. Identifying people at a high risk of developing pancreatic cancer10.1038/nrc3420 ↗
13. Genomic features and clinical management of patients with hereditary pancreatic cancer syndromes and familial pancreatic cancer10.3390/ijms20030561 ↗
14. Detecting early pancreatic cancer: problems and prospects10.1053/j.seminoncol.2007.05.005 ↗
15. Cancer neoantigens10.1146/annurev-immunol-042617-053402 ↗
16. Emerging trends in the immunotherapy of pancreatic cancer10.1016/j.canlet.2017.12.012 ↗
17. Combination of CTLA-4 blockade with MUC1 mRNA nanovaccine induces enhanced anti-tumor CTL activity by modulating tumor microenvironment of triple negative breast cancer10.1016/j.tranon.2021.101298 ↗
18. MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma10.1080/14728222.2017.1323880 ↗
19. Mucins in pancreatic cancer and its microenvironment10.1038/nrgastro.2013.120 ↗
20. Expression of MUC4 mucin is observed mainly in the intestinal type of intraductal papillary mucinous neoplasm of the pancreas10.1097/MPA.0b013e3182965915 ↗
21. Early signals during CD8+ T cell priming regulate the generation of central memory cells10.4049/jimmunol.1000492 ↗
22. On the role of antigen in maintaining cytotoxic T-cell memory10.1073/pnas.93.18.9716 ↗
23. T-cell quality in memory and protection: implications for vaccine design10.1038/nri2274 ↗
24. Engineering a sustained release vaccine with a pathogen-mimicking manner for robust and durable immune responses10.1016/j.jconrel.2021.03.037 ↗
25. Employing ATP as a new adjuvant promotes the induction of robust antitumor cellular immunity by a PLGA nanoparticle vaccine10.1021/acsami.0c15522 ↗
26. Nanoscale coordination polymer based nanovaccine for Tumor immunotherapy10.1021/acsnano.9b05974 ↗
27. Rational design of pathogen-mimicking amphiphilic materials as nanoadjuvants10.1038/srep00198 ↗
28. Polyanhydride nanovaccine induces robust pulmonary B and T cell immunity and confers protection against homologous and heterologous Influenza A virus infections10.3389/fimmu.2018.01953 ↗
29. Polyanhydride nanovaccine platform enhances antigen-specific cytotoxic T cell responses
30. Characterizing the antitumor response in mice treated with antigen-loaded polyanhydride microparticles10.1016/j.actbio.2012.11.001 ↗
31. Polyanhydride nanoparticles induce low inflammatory dendritic cell activation resulting in CD8+ T cell memory and delayed tumor progression10.2147/IJN.S261041 ↗
32. The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response10.1016/j.actbio.2017.01.005 ↗
33. STING pathway stimulation results in a differentially activated innate immune phenotype associated with low nitric oxide and enhanced antibody titers in young and aged mice10.1016/j.vaccine.2019.04.004 ↗
34. Biotinylated streptavidin surface coating improves the efficacy of a PLGA microparticle-based cancer vaccine10.1021/acs.bioconjchem.0c00347 ↗
35. Generation of CTL responses against pancreatic cancer in vitro using dendritic cells co-transfected with MUC4 and survivin RNA10.1016/j.vaccine.2013.07.055 ↗
36. Antibody induction directed against the tumor-associated MUC4 glycoprotein10.1002/cbic.201402689 ↗
37. Amphiphilic polyanhydride-based recombinant MUC4β-nanovaccine activates dendritic cells10.18632/genesandcancer.189 ↗
38. Biomaterial nanocarrier-driven mechanisms to modulate anti-tumor immunity
39. Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β
40. Monoclonal antibodies recognizing the non-tandem repeat regions of the human mucin MUC4 in pancreatic cancer10.1371/journal.pone.0023344 ↗
41. MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy10.1016/j.smim.2020.101391 ↗
42. Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients10.1186/s13073-024-01388-3 ↗
43. A pan-cancer clinical study of personalized neoantigen vaccine monotherapy in treating patients with various types of advanced solid tumors10.1158/1078-0432.CCR-19-2881 ↗
44. Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy10.1371/journal.pone.0080580 ↗
45. Synthesis and characterization of novel polyanhydrides with tailored erosion mechanisms10.1002/jbm.a.30510 ↗
46. Characterization of recombinant β subunit of human MUC4 mucin (rMUC4β)10.1038/s41598-021-02860-5 ↗
47. Design of an injectable system based on bioerodible polyanhydride microspheres for sustained drug delivery10.1016/S0142-9612(02)00181-3 ↗
48. Amphiphilic polyanhydride nanoparticles stabilize Bacillus anthracis protective antigen10.1021/mp2004059 ↗
49. Production of adjuvant-loaded biodegradable particles for use in cancer vaccines10.1007/978-1-4939-6445-1_14 ↗
50. Thermolabile H-2Kb molecules expressed by transporter associated with antigen processing-deficient RMA-S cells are occupied by low-affinity peptides10.4049/jimmunol.163.8.4413 ↗
51. Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity10.1016/0161-5890(94)90155-4 ↗
52. Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro10.1016/0092-8674(90)90020-F ↗
53. Peptide selection by MHC class I molecules10.1038/350703a0 ↗
54. Determining the absolute surface hydrophobicity of microparticulates using thin layer wicking10.1016/S0168-3659(98)00191-6 ↗
55. Enhanced fluorescent intensity of magnetic-fluorescent bifunctional PLGA microspheres based on Janus electrospraying for bioapplication
56. Steinbuck
57. Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells10.1038/s41541-023-00781-0 ↗
58. T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study10.1016/j.ebiom.2024.105317 ↗
59. Durable CD8 T cell memory against SARS-CoV-2 by prime/boost and multi-dose vaccination: considerations on inter-dose time intervals10.3390/ijms232214367 ↗
60. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis10.1158/0008-5472.CAN-03-2636 ↗
61. MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins10.1158/1541-7786.MCR-06-0353 ↗
62. A single dose polyanhydride-based nanovaccine against paratuberculosis infection10.1038/s41541-020-0164-y ↗
63. Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β10.1002/jbm.a.37080 ↗
64. Pathogen-specific T cell polyfunctionality is a correlate of T cell efficacy and immune protection
65. A palette of cytokines to measure anti-tumor efficacy of T cell-based therapeutics10.3390/cancers13040821 ↗
66. Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile10.1080/2162402X.2019.1648170 ↗
67. CD4+ T cells support polyfunctionality of cytotoxic CD8+ T cells with memory potential in immunological control of tumor10.1111/cas.14420 ↗
68. PD-1þ polyfunctional T cells dominate the periphery after tumor-infiltrating lymphocyte therapy for cancer10.1158/1078-0432.CCR-16-1692 ↗
69. Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy10.1182/blood-2011-12-398321 ↗
70. Clonal abundance of tumor-specific CD4+ T cells potentiates efficacy and alters susceptibility to exhaustion10.1016/j.immuni.2015.12.018 ↗
71. Exploiting lymphatic transport and complement activation in nanoparticle vaccines10.1038/nbt1332 ↗
72. Critical size limit of biodegradable nanoparticles for enhanced lymph node trafficking and paracortex penetration10.1007/s12274-019-2301-3 ↗
73. Evaluation of biocompatibility and administration site reactogenicity of polyanhydride-particle-based platform for vaccine delivery10.1002/adhm.201200181 ↗
74. Combinatorial evaluation of in vivo distribution of polyanhydride particle-based platforms for vaccine delivery
75. High throughput cell-based screening of biodegradable polyanhydride libraries10.2174/138620709788923764 ↗
76. Titrating polyarginine into nanofibers enhances cyclic-dinucleotide adjuvanticity in vitro and after sublingual immunization10.1021/acsbiomaterials.0c01429 ↗
77. Just right” combinations of adjuvants with nanoscale carriers activate aged dendritic cells without overt inflammation10.1186/s12979-023-00332-0 ↗
78. Novel nanoadjuvants balance immune activation with modest inflammation: implications for older adult vaccines10.1186/s12979-023-00349-5 ↗
79. Polyanhydride microparticles enhance dendritic cell antigen presentation and activation10.1016/j.actbio.2011.03.023 ↗
80. Polymer chemistry influences monocytic uptake of polyanhydride nanospheres10.1007/s11095-008-9760-7 ↗
81. Cellular internalization mechanisms of polyanhydride particles: implications for rational design of drug delivery vehicles10.1166/jbn.2016.2259 ↗
82. Activation of innate immune responses in a pathogen-mimicking manner by amphiphilic polyanhydride nanoparticle adjuvants10.1016/j.biomaterials.2011.05.063 ↗
83. Chemistry-dependent adsorption of serum proteins onto polyanhydride microparticles differentially influences dendritic cell uptake and activation10.1016/j.actbio.2012.06.001 ↗
84. A promising CpG adjuvant-loaded nanoparticle-based vaccine for treatment of dust mite allergies10.2217/imt.14.97 ↗
85. Polyfunctional responses by human T cells result from sequential release of cytokines10.1073/pnas.1117194109 ↗
86. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major10.1038/nm1592 ↗